LAS VEGAS--(BUSINESS WIRE)--GeoVax Labs, Inc. (OTCBB:GOVX - News), an Atlanta-based biopharmaceutical company developing human vaccines for diseases caused by HIV-1 (Human Immunodeficiency Virus) and other infectious agents, together with VGX International (VGXI), announced today at the International Society of DNA Vaccines Conference, held in Las Vegas, Nevada, the execution of a Master Product Sale Agreement between VGXI and GeoVax, whereby VGXI will manufacture plasmid, namely the JS2-DNA vaccine, for use in GeoVax’s future preventative and therapeutic clinical human trials.

Based on GeoVax’s ongoing research and development, GeoVax plans to phase-in its JS2-DNA vaccine in future human trials, an enhanced DNA version of the present JS7-DNA vaccine, which the company believes will further improve the vaccine’s performance in human trials and possibly yield even stronger results than its already impressive results which were recently reported at conferences held in Cape-town, South Africa and Cambridge, England. GeoVax’s next generation, JS2-DNA vaccine, is planned to be phased-into GeoVax’s human trials in the near future, as it becomes available from its other suppliers and VGXI, a leader in plasmid vaccine development, with its state of the art production facility in The Woodlands, Texas.

“Any time we can achieve even stronger results in these important human trials, it does make sense to use the best technology going forward. Our innovation is what brought us to this level in the first place and we intend to maintain our leadership position, for the good of our shareholders and humanity,” stated Robert McNally, Ph.D., GeoVax’s CEO and President.

“Dr. Harriet Robinson is a true pioneer in the development of DNA vaccines for HIV and other infectious diseases,” said Henry Hebel, Chief Operating Officer of VGXI. “Her work with GeoVax has been instrumental to the advancement of the field, and VGX International is proud to support these efforts. This agreement further solidifies our position as the world’s leading provider of DNA vaccines.”

GeoVax recently announced that its Phase-2a preventative human trial, involving twelve clinical sites across North and South America, is set to start. This JS2-DNA vaccine implementation will have no impact whatsoever on this trial or any other presently ongoing trials. Upon its availability, however, GeoVax plans to phase it in at the earliest opportunity going forward. Regarding GeoVax’s upcoming therapeutic trial, the Company intends to utilize the JS2-DNA vaccine from the start. Sufficient quantities are scheduled to be produced by VGXI and other suppliers to accommodate GeoVax’s initial therapeutic trial needs as well as quantities which will be required for the phase-in program, replacing the JS7-DNA vaccine presently used in the company’s preventative trials.

About GeoVax Labs, Inc.

GeoVax Labs, Inc. is a biotechnology company, established to develop, manufacture, license and commercialize human vaccines for diseases caused by HIV-1 (Human Immunodeficiency Virus) and other infectious agents. GeoVax's AIDS vaccine technology is the subject of 20 issued or filed patent applications. GeoVax AIDS vaccines are designed for use in uninfected people to prevent Acquired Immunodeficiency Disease (AIDS), caused by the virus known as HIV-1, should the person ever become infected. GeoVax AIDS vaccines also may be effective as therapeutics (treatment of people already infected with the HIV-1 virus). Studies evaluating these vaccines in HIV/AIDS infected individuals are in the planning stage.

GeoVax's core AIDS vaccine technologies were developed through a collaboration of colleagues at Emory University's Vaccine Center, the National Institutes of Health (NIH), The Centers for Disease Control and Prevention (CDC) and the GeoVax team.

GeoVax AIDS vaccines have moved forward in human clinical trials conducted by the HIV Vaccine Trials Network (HVTN) based in Seattle, Washington. The HVTN, funded through a cooperative agreement with the National Institutes of Health (NIH), is the largest worldwide clinical trials program dedicated to the development and testing of AIDS vaccines. Preclinical work enabling evaluation of GeoVax DNA and MVA vaccines was funded and supported by NIAID, which provided additional support to GeoVax AIDS vaccine development program with a $15 million IPCAVD grant awarded in late 2007. www.geovax.com

About VGXI, Inc.

VGXI is a leading manufacturer of DNA plasmids, and its cGMP and non-cGMP products have passed rigorous reviews by several international regulatory agencies. VGXI offers a wide variety of contract manufacturing services to outside client organizations. The Company’s cGMP manufacturing facility in The Woodlands, Texas is a flexible, purpose-built facility used for research, development, and clinical supply. The site includes 500-liter and 100-liter fermentors and incorporates a cost-effective process. More information about VGXI can be found at www.vgxii.com.

Safe Harbor Statement: All statements in this news release, not statements of historical fact, are forward-looking statements. These statements are based on expectations and assumptions on the date of this press release and are subject to numerous risks and uncertainties which could cause actual results to differ materially from those described in the forward-looking statements. Risks and uncertainties include, but are not limited to, whether: GeoVax can develop and manufacture these vaccines with the desired characteristics in a timely manner, GeoVax's vaccines will be safe for human use, GeoVax's vaccines will effectively prevent AIDS in humans, vaccines will receive regulatory approvals necessary to be licensed and marketed, GeoVax raises required capital to complete vaccine development, there is development of competitive products that may be more effective or easier to use than GeoVax's products, and other factors over which GeoVax has no control. GeoVax assumes no obligation to update these forward-looking statements, and does not intend to do so. Certain matters discussed in this news release are forward-looking statements involving certain risks and uncertainties including, without limitation, risks detailed in the Company's Securities and Exchange Commission filings and reports.

MULTIMEDIA AVAILABLE: http://www.businesswire.com/cgi-bin/mmg.cgi?eid=5848234

Financial Relations Board
Melanie Nimrodi, 312-546-3508
mnimrodi@frbir.com
or
For GeoVax:
Bob McNally, 404-727-0971
bmcnally@geovax.com
or
For VGXI:
Henry Hebel, 281-296-7300
hhebel@vgxii.com